

# Laura Maria Fogliatto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5392/publications.pdf>

Version: 2024-02-01

33  
papers

1,005  
citations

840776

11  
h-index

610901

24  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1141  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
2	Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. <i>JCO Global Oncology</i> , 2022, 8, e2100265.	1.8	6
3	Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. <i>Journal of Clinical Oncology</i> , 2022, 40, 7539-7539.	1.6	17
4	Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 191-200.	0.2	8
5	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021, 22, 512-524.	10.7	144
6	Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study. <i>Journal of Clinical Oncology</i> , 2021, 39, 7545-7545.	1.6	1
7	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	1.4	147
8	Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. <i>Blood</i> , 2021, 138, 310-310.	1.4	13
9	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL). <i>Blood</i> , 2021, 138, 306-306.	1.4	5
10	Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy. <i>Blood</i> , 2020, 136, 12-12.	1.4	4
11	Efficacy and Safety Results from ASCSEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
19	Efficacy and time to next treatment following lenalidomide/rituximab ( $R^{>2}$ ) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).. Journal of Clinical Oncology, 2019, 37, 7514-7514.	1.6	0
20	Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. Blood, 2018, 132, 46-46.	1.4	4
21	First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia. Clinica Chimica Acta, 2016, 453, 42-47.	1.1	10
22	Results from a Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with NHL. Blood, 2016, 128, 5327-5327.	1.4	2
23	Pharmacogenetic Markers of Treatment Response of Imatinib Mesylate in Chronic Myeloid Leukemia Brazilian Patients. Blood, 2016, 128, 5458-5458.	1.4	0
24	DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application. Bioanalysis, 2015, 7, 2105-2117.	1.5	30
25	Economic Impact of Imatinib Mesylate Withdraw: An Option for Third World Countries?. Blood, 2015, 126, 5161-5161.	1.4	2
26	BCR-ABL Fluctuation Analysis in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients with MR 4.5. Blood, 2015, 126, 5162-5162.	1.4	1
27	Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia. Revista Brasileira De Hematologia E Hemoterapia, 2014, 36, 54-59.	0.7	17
28	The Impact of Early Molecular Response in Event Free Survival in Patients with Chronic Myeloid Leukemia Treated with Imatinib. Blood, 2014, 124, 5536-5536.	1.4	0
29	TKI Treatment Discontinuation: How Many Patients Could Stop Tyrosine Kinase Treatment According to Discontinuation Trials Criteria? Incidence and Prognostic Impact of Deep Molecular Response in a Cohort of Chronic Myeloid Leukemia Patients of South Brazil's Hematology Centers. Blood, 2014, 124, 5542-5542.	1.4	0
30	The Assessment of the European Leukemianet Criteria for Clinicohematologic Resistance and Intolerance to Hydroxyurea in Polycythemia Vera Is Not Easily Applicable in Daily Practice. Blood, 2014, 124, 5550-5550.	1.4	0
31	Warning As Defined By European Leukemia Net 2013 (ELN 2013) In Chronic Phase Chronic Myeloid Leukemia (CP-CML) Corresponds To Warning In The Clinical Practice?. Blood, 2013, 122, 5176-5176.	1.4	0
32	Imatinib Mesilate Versus Allogeneic Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia in First Chronic Phase - A Brazilian Point of View.. Blood, 2007, 110, 1096-1096.	1.4	0
33	Pregnancy during Treatment with Imatinib: A Case Report.. Blood, 2005, 106, 4851-4851.	1.4	1